HC Wainwright Analysts Boost Earnings Estimates for Zura Bio

Zura Bio Limited (NASDAQ:ZURA) – Research analysts at HC Wainwright raised their Q2 2025 earnings estimates for shares of Zura Bio in a note issued to investors on Monday, May 19th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($0.19) per share for the quarter, up from their prior estimate of ($0.21). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Zura Bio’s current full-year earnings is ($0.65) per share. HC Wainwright also issued estimates for Zura Bio’s Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.19) EPS and FY2025 earnings at ($0.76) EPS.

A number of other research firms also recently commented on ZURA. Oppenheimer dropped their target price on shares of Zura Bio from $19.00 to $17.00 and set an “outperform” rating on the stock in a report on Friday, May 9th. Guggenheim reiterated a “buy” rating and issued a $15.00 target price on shares of Zura Bio in a report on Wednesday, March 26th. Finally, Chardan Capital dropped their target price on shares of Zura Bio from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, March 26th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $14.33.

Zura Bio Price Performance

NASDAQ ZURA opened at $1.03 on Wednesday. The company’s 50 day simple moving average is $1.27 and its 200 day simple moving average is $1.92. Zura Bio has a 12 month low of $0.97 and a 12 month high of $6.03. The company has a market capitalization of $70.43 million, a P/E ratio of -1.47 and a beta of 0.05.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02).

Institutional Investors Weigh In On Zura Bio

A number of large investors have recently made changes to their positions in the company. AQR Capital Management LLC acquired a new stake in shares of Zura Bio during the first quarter valued at approximately $72,000. Allostery Investments LP grew its position in Zura Bio by 44.2% during the first quarter. Allostery Investments LP now owns 2,329,384 shares of the company’s stock valued at $3,005,000 after purchasing an additional 714,258 shares in the last quarter. ADAR1 Capital Management LLC grew its position in Zura Bio by 34.9% during the first quarter. ADAR1 Capital Management LLC now owns 2,801,184 shares of the company’s stock valued at $3,614,000 after purchasing an additional 723,933 shares in the last quarter. Armistice Capital LLC grew its position in Zura Bio by 2.4% during the first quarter. Armistice Capital LLC now owns 1,536,000 shares of the company’s stock valued at $1,981,000 after purchasing an additional 36,000 shares in the last quarter. Finally, Forefront Analytics LLC grew its position in Zura Bio by 101.6% during the first quarter. Forefront Analytics LLC now owns 108,308 shares of the company’s stock valued at $140,000 after purchasing an additional 54,574 shares in the last quarter. Institutional investors and hedge funds own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.